CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma: Based on the mechanism of CCR4, Mogamulizumab is a new humanized anti-CCR4 antibody that is currently being used in the clinical treatment of advanced cutaneous T-cell lymphoma (CTCL) (28).